Benefits of proposed faster drug approval in the UK questionable

Benefits of proposed faster drug approval in the UK questionable PharmacoEconomics & Outcomes News 792, p31 - 2 Dec 2017 Benefits of proposed faster drug approval in the UK questionable The UK’s government proposed scheme of accelerated access to new drugs and technologies is unlikely to improve patient outcomes, say professors of health policy from the London School of Economics and Political Science in London, UK. In their comment published in the BMJ, the professors question the benefits of the proposed scheme, which aims to expedite development and approval of promising new technologies, and their adoption in the NHS. The professors caution that, according to research, most products with accelerated approval "do not offer a step change in patient outcomes". The proposal "says too little on expected benefits for patients and wider society," note the professors. They also suggest that another important issue is that the selection process of such promising technologies relies on early studies, which tend to exaggerate benefits. Furthermore, they caution that faster access to new drugs and technologies is more likely to escalate, rather than control healthcare spending. Innovations that save money are very rare, and it is doubtful that the extra costs can be offset by identifying and expediting other products that generate savings. The proposal of accelerated access is a "bold attempt to strike a balance between health and industrial policy," note the professors. They conclude "we should focus on better not faster approvals and send a clear message to industry about the needs and priorities of the NHS and all who use it." Naci H, et al. Accelerated access to new drugs and technologies BMJ : 22 Nov 2017. Available from: URL: 803284964 1173-5503/17/0792-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Dec 2017 No. 792 PharmacoEconomics & Outcomes News Springer Journals

Benefits of proposed faster drug approval in the UK questionable

1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial